Operating cash flow for January–June 2026 was negative $5.39 million, while cash and cash equivalents at the end of June were $25.42 million. Although cash declined from the end of Q1, cash flow from financing activities has not been disclosed, making it important in Q3 to assess cash burn and financing methods.
All recorded disclosures and news since the latest annual or semiannual filing. Switching watchpoints keeps the full history. Select an item to inspect its source.2026-09-10 〜 2026-11-09 · 8 of 8 items
Scroll the timeline →
Whether cash and cash equivalents at the end of June remained at $25,415,921
Whether operating cash flow for January–September 2026 deteriorated further from negative $5,390,262
Whether the composition of the $1,913,494 decrease in cash from $27,329,415 at the end of Q1 is explained
Whether cash flow from financing activities, the amount raised, and funding contributions from partners are disclosed
Operating cash flow for the period from 1 January to 30 June 2026 was negative $5,390,262. Cash and cash equivalents at the end of June were $25,415,921, while the operating loss for the same interim period was negative $5,376,995 and the net loss was negative $4,900,397. Looking only at the narrower losses may suggest an improvement, but the amount of cash actually being consumed by the company as a research and development-focused business must be assessed through operating cash flow.
Cash declined by $1,913,494, from $27,329,415 as of 31 March to $25,415,921 as of 30 June. While interim cash flow from investing activities was small at negative $10,825, cash flow from financing activities was not disclosed. As a result, the entire decrease in cash cannot be explained solely by the operating deficit, and the next materials should be reviewed for any capital raising, borrowing or foreign-exchange translation effects.
The company states that it is difficult to reasonably calculate a full-year earnings forecast and does not guarantee that it can secure sufficient funding to execute all research and development programs as planned. The current materials do not provide the number of months of runway available to fund research and development expenses from the cash balance, funding requirements for the next 12 months or a spending plan by trial. If operating cash flow deteriorates at a faster pace than the losses, the prioritisation of clinical development and financing terms will become key issues.
In the next FY2026-Q3 results, the nine-month cumulative operating cash flow, period-end cash, and cash flow from investing and financing activities should be reviewed together. In particular, if there are additional trial costs for MN-001 or MN-166, research and development costs borne by partners, or financings such as a private placement, it will be important to see whether the amount and timing are disclosed. If cash flow from financing activities remains undisclosed, visibility into the recurrence of cash declines and the company’s liquidity position will remain low.
US$ millions (cash and cash equivalents at period-end)
Select a value or step to inspect its source.
Ordered by date. Disclosures and financial records differ from news and company threads; open each source to inspect it.
2026-11-13 · Awaiting publication
No financial history is available in this briefing yet. Company disclosures can also be checked on the company page.